Peter Joyce, Grey Wolf Therapeutics CEO
May 23, 2024 05:47 AM EDT
Financing
Startups

Grey Wolf reels in $50M to ex­pand in­to au­toim­mune dis­eases

Kyle LaHucik

Senior Reporter

Grey Wolf Ther­a­peu­tics raised an­oth­er $50 mil­lion, which is set to ex­tend its run­way through 2026 and fund an­oth­er clin­i­cal tri­al, this time in au­toim­mune …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times